Escalon Medical 's ROA from the fourth quarter of 2026 to the fourth quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Escalon Medical 's ROA in the fourth quarter of 2026?
Escalon Medical Corp achieved a return on average assets (ROA) of 42.96 % in its fourth quarter of 2026 a new company high.

ROA has improved compared to 29.2% in the third quarter of 2026, due to net income growth.

However, within the Healthcare sector 23 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 2734, from total ROA ranking in the third quarter of 2026 at 3280.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) IV. Quarter	(Mar 31 2026) III. Quarter	(Dec 31 2025) II. Quarter	(Sep 30 2025) I. Quarter	(Jun 30 2025) IV. Quarter
Y / Y Total Assets Change	82.81 %	44.43 %	58.01 %	-0.36 %	58.01 %
Y / Y Net Income Change	208.68 %	-	-	-	329.37 %
Net Income (TTM) in million	3	2	0	0	0
Return On Assets (TTM)	42.96 %	29.2 %	5.48 %	2.33 %	8.97 %
ESMC's Total Ranking	# 2734	# 3280	# 2780	# 2971	# 2906
Total Assets (TTM) in million	9	8	5	5	5
Seq. Total Assets Change	21.19 %	50.85 %	8.98 %	-8.24 %	-4.26 %
Seq. Net Income Change	46.12 %	2046.3 %	-	-	-

ESMC's 5 Years Annual ROA >> Back to ESMC Management Effectiveness >> Compare ESMC ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 5
Sector	# 24
Overall	# 99

Return On Assets Statistics
High	Average	Low
42.96 %	-5.89 %	-63.4 %
(Jun 30 2026)		(Dec 31 2013)

Financial Statements
Escalon Medical 's Assets	$ 9 million	ESMC's Balance sheet
Escalon Medical 's Income	$ 2 million	Quarterly ESMC's Income Statement
ESMC's Income by Division		See ESMC's Income by Division

Annual Return On Assets	(Jun 30 2026) FY 2026	(Jun 30 2025) FY 2025	(Jun 30 2024) FY 2024	(Jun 30 2023) FY 2023	(Jun 30 2022) FY 2022
Y / Y Total Assets Change	115.82 %	38.67 %	-18.95 %	10.26 %	-17.65 %
Total Assets in million	9	4	3	4	4
Y / Y Net Income Change	4940.99 %	-	-	1408.84 %	-
Net Income in million	4	0	0	0	0
Annual Return On Assets	42.43 %	1.82 %	-3.97 %	7 %	0.51 %

ESMC's 5 Years Annual ROA >> Back to ESMC Management Effectiveness >> Compare ESMC ROA to its Competitors

Comment on ESMC's ROA in the fiscal year ending 2026

In the fiscal year 2026 ROA improved to 42.43 % compared to prior year, due to annual net income growth of 4940.99 % to $4.01 million, while value of Escalon Medical 's overall assets grew just by 115.82 % to $9.46 million, compared to $9.46 a year before.

More Return On Assets Ratios
ESMC's' Return on Assets at Yahoo Finance
Medical Equipment & Supplies Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
ESMC's Roa Ratio versus Medical Equipment & Supplies Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for ESMC's Competitors
Subscribers only: Roa for Escalon Medical 's Suppliers
Subscribers only: Return On Assets for ESMC's Customers

You may also want to know
ESMC's Roi	ESMC's Inventory Turnover Ratio	ESMC's Growth Rates	ESMC's Dividend Comparisons
	ESMC's Profitability Ratios	ESMC's Asset Turnover Ratio	ESMC's Dividend Growth
ESMC's Roe	ESMC's Valuation Ratios	ESMC's Financial Strength Ratios	ESMC's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector	ROA
Elutia Inc	108.72 %
Silexion Therapeutics Corp	99.09 %
Quince Therapeutics Inc	88.46 %
Interpace Biosciences Inc	85.91 %
Arbutus Biopharma Corp	82.34 %
Oncotelic Therapeutics Inc	81.75 %
Advanced Biomed Inc.	76.09 %
Rigel Pharmaceuticals Inc	72.27 %
Actinium Pharmaceuticals Inc	71.73 %
Exelixis Inc	70.51 %
Rallybio Corporation	64.51 %
Oramed Pharmaceuticals Inc	64.18 %
Fortress Biotech Inc	60.88 %
Atlantic Coastal Acquisition Corp Ii	54.09 %
Lensar Inc	47.48 %
Elite Pharmaceuticals Inc	46.11 %
Omeros Corporation	46.05 %
Q32 Bio Inc	45.18 %
Aurinia Pharmaceuticals Inc	44.95 %
Agenus Inc	44.86 %
Earth Science Tech Inc	44.02 %
Escalon Medical Corp	42.96 %
Sanuwave Health Inc	39.15 %
Liquidia Corporation	36.30 %
Ironwood Pharmaceuticals inc	34.34 %
Idexx Laboratories Inc	33.61 %
Tg Therapeutics Inc	33.59 %
Meiragtx Holdings Plc	29.37 %
Indivior Pharmaceuticals Inc	28.21 %
Qhslab Inc	27.12 %

Date modified: 2026-10-17T15:14:49+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.